Andrija Vuković

Dr. Andrija Vuković

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2023 in Fractal and Fractional
Verified
Journal Article
Open access
PDF file
VMVedrana Makevic
Vedrana Makevic
IMIvan D. Milovanovich
Ivan D. Milovanovich
NPNevena Popovac
Nevena Popovac
Radmila M. JankovicRadmila M. Jankovic
Radmila M. Jankovic
JTJelena Trajkovic
Jelena Trajkovic
Andjelija IlićAndjelija Ilić
Andjelija Ilić
Inflammatory bowel disease (IBD), which encompasses two different phenotypes—Crohn’s disease (CD) and ulcerative colitis (UC)—consists of chronic, relapsing disorders of the gastrointestinal tract. In 20–30% of cases, the disease begins in the pediatric age. There have been just a few studies that used fractals for IBD investigation, but none of them analyzed intestinal cell chromatin. The main aim of this study was to assess whether it is possible to differentiate between the two phenotypes in pediatric patients, or either of the phenotypes versus control, using the fractal dimension and lacunarity of intestinal cell chromatin. We analyzed nuclei from at least seven different intestinal segments from each group. In the majority of colon segments, both the fractal dimension (FD) and the lacunarity significantly differed between the UC group and CD group, and the UC group and control group. In addition, the ileocecal valve and rectum were the only segments in which CD could be differentiated from the controls based on the FD. The potential of the fractal analysis of intestinal cell nuclei to serve as an observer-independent histological tool for ulcerative colitis diagnosis was identified for the first time in this study. Our results pave the way for the development of computer-aided diagnosis systems that will assist the physicians in their clinical practice.

9 December 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
AVAndrija Vuković
Andrija Vuković
Danijela KaranovicDanijela Karanovic
Danijela Karanovic
NMNevena Mihailovic-Stanojevic
Nevena Mihailovic-Stanojevic
ZMZoran Miloradović
Zoran Miloradović
Predrag BrkicPredrag Brkic
Predrag Brkic
SLSilvio R De Luka
Silvio R De Luka
Background/Objectives: Chronic kidney disease (CKD) is a progressive pathological condition which results in the severe fibrosis of the kidneys. However, the mechanisms of CKD progression and fibrogenesis remain unclear. We wanted to examine the effects that apocynin and hyperbaric oxygen therapy (HBOT) have on renal function and structure in animals with CKD induced through 5/6 nephrectomy (5/6 Nx-L). Methods: Male Wistar rats were divided in 5 groups (n = 8/group) as follows: control—sham-operated rats; Nx-L—rats with 5/6 Nx-L; APO—5/6 Nx-L + apocynin treatment; HBOT—5/6 Nx-L + hyperbaric oxygen treatment, and APO+HBOT—5/6 Nx-L, treated with both treatments. All treatments started 4 weeks after the final step of CKD induction and lasted for 4 weeks. At the end of the experiment, urine samples were collected for the proteinuria assessment and the mean arterial pressure (MAP) was measured. Kidneys were collected for histopathological, Western blot, and immunohistochemical analyses. Results: All treatments significantly decreased MAP compared to the Nx-L group (p < 0.001). In the APO and APO+HBOT groups, the level of proteinuria was decreased compared to the Nx-L group (p < 0.05 and p < 0.01, respectively). All examined treatments significantly decreased the intensity of lesions in the kidney compared to those observed in the Nx-L group (p < 0.001). Isolated treatments with apocynin and HBOT induced a significant decrease in desmin expression compared to the Nx-L group (p < 0.05); meanwhile, they did not affect the levels of fibronectin (FN) and hypoxia-inducible factor-1α (HIF-1α). Combined treatment did not affect desmin expression levels; however, it induced a significant increase in fibronectin expression compared to Nx-L (p < 0.001). Conclusions: Apocynin treatment decreased BP and protein loss, and it improved renal morphology at least partly through the downregulation of desmin expression without changing FN and HIF-1α. Hyperbaric oxygen therapy improved hypertension but failed to significantly affect the level of proteinuria. Combined treatment (apocynin and HBOT) normalized blood pressure (BP) values, renal function, and improved kidney structure by modulating FN and HIF-1α, without affecting desmin protein expression. Further studies are needed to elucidate the mechanisms of slowing down the progression of CKD in this experimental model.

21 August 2025 in Antioxidants
Verified
Journal Article
Open access
PDF file
JOJelena Nesovic Ostojic
Jelena Nesovic Ostojic
Sanjin KovacevicSanjin Kovacevic
Sanjin Kovacevic
SLSilvio R De Luka
Silvio R De Luka
MIMilan Ivanov
Milan Ivanov
Aleksandra NenadovicAleksandra Nenadovic
Aleksandra Nenadovic
AVAndrija Vuković
Andrija Vuković
Acute kidney injury (AKI) is characterized by a sudden rise in serum creatinine levels, a reduction in urine output, or both. Despite its frequent occurrence in clinical settings, AKI remains poorly understood from a pathophysiological standpoint. As a result, management primarily relies on supportive care rather than targeted treatments. Emerging evidence underscores the pivotal role of oxidative stress in both the initiation and progression of AKI, thereby identifying it as a potential therapeutic target. This review aims to comprehensively examine the pharmacological effects and underlying mechanisms of apocynin (APO) in the context of AKI, with a particular focus on ischemia–reperfusion injury (IRI) and nephrotoxic-induced AKI. Experimental preclinical studies have consistently demonstrated that APO offers protective effects primarily through its inhibition of NADPH oxidase-mediated oxidative stress. In renal IRI and drug-induced nephrotoxicity models, APO has been shown to attenuate oxidative damage, reduce inflammatory responses, and preserve renal structure and function. These results suggest that it may serve as an effective treatment for reducing kidney damage caused by acute ischemia or exposure to nephrotoxic agents. Although the results are encouraging, further investigation is required to establish the optimal dosing strategy and treatment protocol, as well as to confirm the translational relevance of these findings in human clinical settings.

6 March 2026 in Biological Trace Element Research
Verified
Journal Article
Closed access
PDF file
AVAndrija Vuković
Andrija Vuković
Danijela KaranovicDanijela Karanovic
Danijela Karanovic
Predrag BrkicPredrag Brkic
Predrag Brkic
SJSasa Jankovic
Sasa Jankovic
JOJelena Nesovic Ostojic
Jelena Nesovic Ostojic
SLSilvio R De Luka
Silvio R De Luka

8 August 2026 in Biomedical Signal Processing and Control
Verified
Journal Article
Closed access
IMIvan D. Milovanovich
Ivan D. Milovanovich
VMVedrana Makević
Vedrana Makević
NPNevena Popovac
Nevena Popovac
Radmila M. JankovicRadmila M. Jankovic
Radmila M. Jankovic
JTJelena Trajković
Jelena Trajković
AIAndjelija Ž. Ilić
Andjelija Ž. Ilić

1 January 2025
Verified
Conference Paper
Closed access
JOJelena Nesovic Ostojic
Jelena Nesovic Ostojic
Sanjin KovacevicSanjin Kovacevic
Sanjin Kovacevic
NMNikola Mitovic
Nikola Mitovic
Aleksandra NenadovicAleksandra Nenadovic
Aleksandra Nenadovic
AVAndrija Vuković
Andrija Vuković
MJMirjana Jovanović
Mirjana Jovanović
Renal function is an important aspect to evaluate in cardiovascular patients because kidney function and heart function are closely interconnected. Cardiorenal syndrome refers to this complex relationship, where either heart or kidney dysfunction can lead to worsening of the other, making their management more complex and challenging. Renal function in cardiovascular patietns should be assessed at the time of diagnosis of cardiovascular conditions (e.g., heart failure, coronary artery disease, or hypertension), as kidney function can impact the treatment plan and prognosis; during hospitalization, when patietns are admitted for conditions like heart failure, renal function should be evaluated to monitor for acute kidney injury (AKI) or worsening chronic kidney disease (CKD). After surgeries such as coronary artery bypass grafting or valve replacement, renal function should be closely monitored due to the risk of postoperative renal complications. If a patient with known cardiovascular disease develops new or worsening symptoms (e.g., edema, dyspnea, or fatigue), renal function should be evaluated as it may indicate worsening heart failure or fluid overload. Certain cardiovascular drugs (like ACE inhibitors, ARBs, diuretics, and anticoagulants) are cleared by the kidneys, and renal function should be assessed to adjust doses and minimize the risk of toxicity. For patients with a known history of CKD, regular renal function evaluation is important for monitoring disease progression and managing cardiovascular risk. It is also essential to regularly evaluate renal function in patients with hypertension, diabetes, or metabolic syndrome that are risk factors for both cardiovascular and kidney diseases. Evaluating renal function in cardiovascular patients is essential to: detect and manage cardiorenal syndrome early; adjust cardiovascular medication dosages and avoid toxicities; guide fluid and electrolyte management; reduce cardiovascular and renal complications, and imrove prognosis and quality of life. By closely monitoring renal function, clinicians can optimize both cardiovascular and renal outcomes, helping to prevent complications and improve the overall health of these patients. Serum creatinine is a standard measure of kidney function. From serum creatinine, the eGFR is calculated to assess kidney function. A decline in eGFR (usually <60 mL/min/1.73m²) indicates reduced kidney function. eGFR may be overestimated in patients with high muscle mass or malnutrition, and underestimating kidney function in patients with obesity or edema. Particularly in hospitalized or critically ill patients, urine output is an important marker of renal function. Decreased urine output (oliguria) may indicate acute kidney injury or worsening heart failure. Proteinuria and hematuria can indicate kidney damage. In patients with heart failure, proteinuria may be a sign of kidney involvement and should be assessed regularly. BUN is another marker of kidney function but is less specific than creatinine and can be influenced by factors such as dehydration, diet, and liver function. Electrolytes (e.g., potassium, sodium, and bicarbonate) should be monitored, as disturbances in electrolyte balance (e.g., hyperkalemia, hyponatremia) are common in patients with kidney dysfunction and heart failure. Neurohormonal biomarkers like BNP (B-type natriuretic peptide) or proBNP can be elevated in both heart failure and renal dysfunction. Evaluating these levels can help assess the severity of heart failure and guide management. A rise in creatinine levels or a decrease in urine output can indicate AKI. Monitoring trends in these values can help in early identification and intervention. Risk scoring: Use of scoring systems like the RIFLE (Risk, Injury, Failure, Loss, End-stage renal disease) or AKIN (Acute Kidney Injury Network) criteria may help in determining the severity of AKI.